The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
El Mundo on MSN12d
New advance against HIV: a single annual injection against the infectionData from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
Face2Face Africa on MSN6d
White model who injected skin to become Black reveals plans to ‘move to Africa’A white model who had a subcutaneous injection to become black has revealed her intentions of moving to Africa in the next ...
Queerty on MSN12d
A once-a-year PrEP injection? The results of the first clinical trial look promisingPharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The company revealed its results at this week’s Conference on Retroviruses and ...
Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus ...
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback